Abstract
The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Current Pharmaceutical Design
Title: Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases
Volume: 15 Issue: 28
Author(s): Antonis K. Moustakas and George K. Papadopoulos
Affiliation:
Keywords: APL, autoimmunity, HLA, MHC, vaccines
Abstract: The Major Histocompatibility Complex Class II locus is the primary genetic linkage to autoimmune diseases. Susceptibility to each such disease is linked to different alleles, with a few alleles showing also dominant protection. The design of vaccines for autoimmune diseases is a long sought-after goal. As knowledge about the pathogenesis of these diseases has increased, the tools for such an approach have of necessity been refined. We review below the structural essence of MHC II-linked autoimmune diseases which centers on the binding of antigenic peptides to the disease-linked MHC II proteins, and the consequent activation of cognate TCRs from pathogenic CD4+ T cells. The state of affairs in two organ-specific autoimmune diseases, type 1 diabetes, celiac disease are covered, including attempts to treat these via antigen-specific MHC II-guided measures. We offer a couple of testable suggestions as to how this approach could be improved.
Export Options
About this article
Cite this article as:
Moustakas K. Antonis and Papadopoulos K. George, Use of MHC II Structural Features in the Design of Vaccines for Organ-Specific Autoimmune Diseases, Current Pharmaceutical Design 2009; 15 (28) . https://dx.doi.org/10.2174/138161209789105117
DOI https://dx.doi.org/10.2174/138161209789105117 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chitosan Nanoparticles: A Therapeutic Carrier for Delivery of DNA, siRNA and CpG-ODNs
Nanoscience & Nanotechnology-Asia Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews The Impact of Infection on the Incidence of Autoimmune Disease
Current Topics in Medicinal Chemistry IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Migraine in Systemic Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design The Janus Face of CD4+CD25+ Regulatory T Cells in Cancer and Autoimmunity
Current Medicinal Chemistry Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Rheumatoid Arthritis: Conjugating Basics with Drug Delivery
Current Rheumatology Reviews KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Control of Interleukin-1β Secretion in Inflammation and Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Current Drug Targets ‘Toll’ Gates for Future Immunotherapy
Current Pharmaceutical Design B-Cell Based Gene Therapy for Inducing Tolerance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetic Regulation of Regulatory T Cells in Kidney Disease and Transplantation
Current Gene Therapy Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design Glucocorticoids Pharmacology: Past, Present and Future
Current Pharmaceutical Design